Detection of West Nile virus RNA and antibody in frozen plasma components from a voluntary market withdrawal during the 2002 peak epidemic
- 22 March 2005
- journal article
- Published by Wiley in Transfusion
- Vol. 45 (4), 480-486
- https://doi.org/10.1111/j.0041-1132.2005.04266.x
Abstract
The US West Nile virus (WNV) epidemic in the summer and fall of 2002 included the first documented cases of transfusion-transmitted WNV infection. In December 2002, the FDA supported a voluntary market withdrawal by the blood banking community of frozen blood components collected in WNV high-activity areas. At the time, the prevalence of viremia and serologic markers for WNV in the blood supply was undefined. In collaboration with America's Blood Centers, 1468 frozen plasma components (of approx. 60,000 frozen units voluntarily withdrawn from the market) were selectively retrieved from the peak epidemic regions and season (June 23, 2002-September 28, 2002). These units were unlinked, subaliquoted, and tested by WNV enzyme immunoassays (EIAs; Focus Technologies and Abbott Laboratories) and nucleic acid amplification tests (NATs; Gen-Probe Inc. and Roche Molecular Systems). Of the 1468 EIA results from Abbott and Focus, 7 were anti-immunoglobulin M (IgM)- and anti-immunoglobulin G (IgG)-reactive by both assays, 8 and 1 were IgM-only-reactive, and 8 and 23 were IgG-only-reactive, respectively. NAT by Gen-Probe and Roche Molecular Systems yielded one RNA-positive, antibody-negative unit containing approximately 440 RNA copies per mL. An additional 10-fold replicate NAT testing by Gen-Probe on 14 of 15 IgM-reactive specimens yielded 2 additional IgM- and IgG-reactive units with low-level viremia (i.e., 7/10 and 2/10 replicates tested reactive). The prevalence of acute (RNA-positive) and recent (IgM-seroreactive) WNV infections indicates that transfusion risk in high-risk areas could have been considerable and that voluntary market withdrawal of frozen components likely averted some WNV transfusion transmissions. The existence of very-low-level viremic units raises concerns, because WNV minipool NAT screening will miss such units and individual NAT may not completely correct this situation.Keywords
This publication has 16 references indexed in Scilit:
- Experimental Infection of Rhesus Macaques with West Nile Virus: Level and Duration of Viremia and Kinetics of the Antibody Response after InfectionThe Journal of Infectious Diseases, 2004
- Utility of the Focus Technologies West Nile Virus Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assay for Testing Cerebrospinal FluidJournal of Clinical Microbiology, 2004
- Emerging Infections, Transfusion Safety, and EpidemiologyNew England Journal of Medicine, 2003
- Transmission of West Nile Virus through Blood Transfusion in the United States in 2002New England Journal of Medicine, 2003
- Detection of West Nile Virus (WNV)-Specific Immunoglobulin M in a Reference Laboratory Setting during the 2002 WNV Season in the United StatesClinical and Vaccine Immunology, 2003
- Transfusion transmission of West Nile virus: a merging of historical and contemporary perspectivesTransfusion, 2003
- The Emergence of West Nile Virus in North America: Ecology, Epidemiology, and SurveillancePublished by Springer Nature ,2002
- The Outbreak of West Nile Virus Infection in the New York City Area in 1999New England Journal of Medicine, 2001
- West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent AssaysJournal of Virology, 2001
- West Nile Fever–a Reemerging Mosquito-Borne Viral Disease in EuropeEmerging Infectious Diseases, 1999